Australia Allows Industry Collaboration To Continue
GBMA And Medicines Australia Get One-Year Extension From ACCC
Executive Summary
Australia’s competition authority has extended the arrangements allowing local off-patent industry body the GBMA to closely collaborate with brand organization Medicines Australia to co-ordinate supply against the backdrop of the ongoing COVID-19 pandemic.
You may also be interested in...
Australian Industry Working To Minimize Medicines Shortages
Australia’s branded and generic drug industry associations have jointly raised concerns about the impact ongoing shortages could have on the country’s supply of medicines.
Covid-19: Australian Competition Body Confirms Industry Collaboration Conditions
A collaboration between the Australian Generic and Biosimilar Medicines Association and brand industry body Medicines Australia against the backdrop of COVID-19 has been endorsed through a final determination from the country’s competition body that clarifies the conditions of the ongoing arrangement.
Australian Body Confirms Collaboration Conditions
A collaboration between the Australian Generic and Biosimilar Medicines Association and brand industry body Medicines Australia against the backdrop of COVID-19 has been endorsed through a final determination from the country’s competition body that clarifies the conditions of the ongoing arrangement.